A research team led by a Michigan State University professor has discovered a link between diabetes and bone marrow nerve damage that may help treat one of the disease’s most common and potentially blindness-causing complications.
The key to better treating retinopathy — damage to blood vessels in the retina that affects up to 80% of diabetic patients — lies not in the retina but in damage to the nerves found in bone marrow that leads to the abnormal release of stem cells, said Julia Busik, an associate professor in MSU’s Department of Physiology, East Lansing, MI.
“With retinopathy, blood vessels grow abnormally in the retina, distort vision and eventually can cause blindness,” said Busik, whose research was published. “There has been a lot of progress in treating the complication, but most treatments use a laser that is painful to the patient and destroys parts of the retina.”
Busik and her team found that nerve damage in diabetic bone marrow — where stem cells known as endothelial progenitor cells reside — affects the daily release of those EPC’s into the bloodstream. Normally EPC’s would exit the bone marrow and repair damage done in the vascular system during sleep.
Using animal models, the research team observed that the pattern of EPC release is faulty in diabetic bone marrow, creating abnormally low levels of EPC’s during sleep, when they are needed most. That decrease in EPC release from a diabetic patient’s bone marrow preceded the development of retinopathy.
“When the bone marrow suffers nerve damage in diabetic patients, it no longer provides a signal for the timely release of these reparative stem cells,” Busik said. This novel finding shows that bone marrow nerve damage represents a new therapeutic target for treatment of all diabetic vascular complications, such as retinopathy.
“This opens up new avenues to better treatments outside of the retina that focus on stem cells and the causes of the nerve damage in bone marrow,” said Busik, whose collaborators included other researchers from MSU and the University of Florida. “We know what happens in the retina and have treatments that are very invasive; we now can look at a host of other options.”
Those options include looking at ways to prevent the original nerve damage in the bone marrow and potentially repairing or replacing the damaged endothelial progenitor cells.
Journal of Experimental Medicine, December 2009